Prisons Keep Hepatitis C Cures Under Lock and Key
State prisoners have a higher-than-average rate of hepatitis C infection, but their chances of accessing a cure are uncommonly slim. A new study from Health Affairs reveals that less than 1 percent of prisoners with hepatitis C can get direct-acting antiviral treatments for the chronic disease. The study included 106,200 inmates across 41 state prison systems.
Orphan Drug Access Still Eludes Some Cystic Fibrosis Patients
More than a year after a breakthrough drug for cystic fibrosis became available, fewer than half of patients who meet the Food and Drug Administration’s criteria can actually access the medication.
IfPA White Paper Explores Access to Emerging Treatments for Alzheimer’s, Parkinson’s
Millions of Americans and their families struggle every day with the devastating effects of Alzheimer’s, Parkinson’s and Huntington’s diseases.
IfPA Cautions ICER against “Discriminating” Among Psoriasis Treatments
Evaluating cost effectiveness is one thing; using value assessments to rank patients’ treatment options is quite another.
WHO Meeting Looks Forward on Distinguishable Names
This month’s World Health Organization Open Sessions with INN Stakeholders explored the value, and the future, of the biological qualifier system. The Global Alliance for Patient Access was pleased to present to WHO officials and an international group of fellow stakeholders.
Awareness Month Highlights Breast Cancer Disparities & Access Challenges
Breast Cancer Awareness Month, celebrated this October, invites public dialogue about screening, risk factors and the value of early detection.
NCfIH Marks RSV Awareness Month with Release of New “Fast Facts”
October marks the beginning of both the RSV viral season and RSV awareness month. The National Coalition for Infant Health is taking the opportunity to release a new “Fast Facts” educational resource on the virus, its impact, and its danger for infants, especially preemies whose health plans don’t cover preventive treatment.
Nordic Patient Groups Tackle Biosimilar Policy Issues
Biosimilar medicines are being prescribed more and more freely across Europe. But access to, and use of, these new medicines differs greatly depending on which European country you live in.
New IfPA Data Support Non-Medical Switching Concerns
Preliminary data from the Institute for Patient Access suggest what opponents of non-medical switching have long suspected: having medications switched for financial reasons could be bad news for patients with chronic diseases.
New Report: Biosimilar Cost Savings Won’t Reach Patients
Since the advent of biosimilars, experts and pundits have debated how reduced biosimilar prices will be and just much savings the follow-on drugs will offer.
